Skip to main content
. 2018 Aug 7;26(10):2487–2495. doi: 10.1016/j.ymthe.2018.08.001

Figure 4.

Figure 4

Anti-LILRB4 CAR-T Cells Significantly Reduce Leukemia Burden in the MV4-11 AML Xenograft Mouse Model

NSG mice were irradiated on day −1, injected with MV4-11 AML cells on day 0, and treated with PBS, control (untransduced) T cells, or anti-LILRB4 CAR-T cells on day 5. (A) Weekly BLI of mice treated with PBS, control T cells, and anti-LILRB4 CAR-T cells. (B) Plot of total flux (p/s) as a function of time demonstrates that anti-LILRB4 CAR-T cell-treated mice had significantly decreased leukemia burden as compared with PBS and control T cell-treated mice (PBS: n = 3, control T cell [CN-T]: n = 9, CAR-T: n = 9; **p < 0.01). (C) Percent human leukemia blasts in peripheral blood on day 28. Anti-LILRB4 CAR-T cell-treated mice show significantly decreased circulating leukemia blasts in peripheral blood compared with control-T cell-treated mice (*p < 0.05) (left). Anti-LILRB4 CAR-T cells found to be persistent in PB at 28 days (right). (D) Left: percent human leukemia blasts in bone marrow on day 37, representative mice flow cytometry plot. Right: bone marrow harvested and analyzed for presence of LILRB4+ AML cells from mice sacrificed on days 28–37 demonstrated significantly reduced marrow leukemia burden in anti-LILRB4 CAR-T cell-treated mice compared with control (n = 3 for each group; **p < 0.01). (E) Survival analysis of anti-LILRB4 CAR-T cell-treated mice and PBS-treated mice (PBS: n = 6, CN-T: n = 8, CAR-T: n = 8; *p < 0.05). Data are represented as mean ± SE.